XML 62 R44.htm IDEA: XBRL DOCUMENT v3.3.1.900
Net Product Sales (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Revenue Disclosure [Line Items]        
Branded Prescription Drug Fee   $ 40,600    
Net product sales $ 2,689,478 $ 1,750,762 $ 1,425,839  
Risks and Uncertainties [Abstract]        
Concentration risk, percentage 68.00% 70.00%    
Activity of Sales Related Deductions [Roll Forward]        
Balance $ 55,249 $ 24,781 24,601 $ 18,826
Provision related to current period sales 193,190 111,855 89,875  
Credits/payments (162,722) (111,675) (84,100)  
Rebates and Chargebacks        
Activity of Sales Related Deductions [Roll Forward]        
Balance 6,419 3,083 4,400 2,983
Provision related to current period sales 61,124 33,117 25,936  
Credits/payments (57,788) (34,434) (24,519)  
Distribution Related Fees        
Activity of Sales Related Deductions [Roll Forward]        
Balance 48,313 21,166 19,663 15,298
Provision related to current period sales 122,466 77,160 62,984  
Credits/payments (95,319) (75,657) (58,619)  
Other Sales Related Deductions        
Activity of Sales Related Deductions [Roll Forward]        
Balance 517 532 538 $ 545
Provision related to current period sales 9,600 1,578 955  
Credits/payments $ (9,615) $ (1,584) $ (962)  
Customer concentration risk | Gross Sales Revenue        
Risks and Uncertainties [Abstract]        
Concentration risk, percentage 67.00% 73.00% 76.00%  
EYLEA        
Revenue Disclosure [Line Items]        
Net product sales $ 2,676,000 $ 1,736,400 $ 1,408,700  
ARCALYST        
Revenue Disclosure [Line Items]        
Net product sales $ 13,500 $ 14,400 $ 17,100